Arsanis to Present at the 28th European Congress of Clinical Microbiology and Infectious Diseases
17 April 2018 - 2:00PM
Business Wire
Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical
company focused on applying monoclonal antibody (mAb)
immunotherapies to address serious infectious diseases, announced
today that the company will present five scientific posters at the
28th European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID) in Madrid, Spain from April 21 – 24,
2018. The posters will highlight new research findings and
supportive data across all mAb programs in Arsanis’ pipeline.
The following abstracts will be presented at ECCMID as an
exchange of scientific and clinical information (all times
CEST):
ASN100-related
abstractsPoster Presentation: #1006; Sunday, April 22,
1:30 – 2:30 p.m.Genotyping of Staphylococcus aureus links nasal
carriage to lower airway colonization in mechanically ventilated
patientsLead author: L. Stulik
ASN500-related
abstractPoster Presentation: #0021; Saturday, April 21,
3:30 – 4:30 p.m.Functional characterization of highly potent human
monoclonal antibodies targeting different antigenic sites on the
pre-fusion RSV-F proteinLead author: H. Rouha
ASN300-related
abstractPoster Presentation: #1403; Monday, April 23,
12:30 – 1:30 p.m.Serum sensitivity of Klebsiella pneumoniae
correlates with the O-serotype and determines the mechanisms
required for mAb-based protection from infectionLead author: G.
Nagy
ASN200-related
abstractsPoster Presentation: #0913; Sunday, April 22,
12:30 – 1:30 p.m.ST131-O25b is the dominant clone among Escherichia
coli airway colonizers in mechanically ventilated patients: a
prospective studyLead author: L. Guachalla
Poster Presentation: #1409; Monday, April 23, 12:30 – 1:30
p.m.Elucidation of the role of the complement system in killing
Escherichia coli by using in vitro reconstituted complement
pathwaysLead author: M. Mutti
About ArsanisArsanis, Inc. is a clinical-stage
biopharmaceutical company focused on applying monoclonal antibody
(mAb) immunotherapies to address serious infectious diseases. A
deep understanding of the pathogenesis of infection, paired with
access to some of the most advanced mAb discovery techniques and
platforms available today, has positioned Arsanis to
build and advance a pipeline of novel mAbs with multiple mechanisms
of action and high potency against their intended targets. The
company’s lead clinical program, ASN100, is aimed at serious
Staphylococcus aureus infections and is being evaluated in a
Phase 2 clinical trial for the prevention of S.
aureus pneumonia in high-risk, mechanically ventilated
patients. In addition to ASN100, the Arsanis preclinical pipeline
is comprised of mAbs targeting multiple serious bacterial and viral
pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham,
Massachusetts, with European research and preclinical development
operations headquartered in Vienna, Austria (Arsanis
Biosciences GmbH).
For more information, please visit the Arsanis website at
www.arsanis.com.
Cautionary Note Regarding Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include those regarding Arsanis’
plans, strategies and expectations for the clinical development of
its mAb programs; the expected benefits of the option and license
agreement for ASN200; and the potential benefit of its strategic
plans and focus. The words “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,”
“could,” “potential,” “possible,” “hope,” “strategy,” “milestone,”
“will,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from
Arsanis' current expectations and beliefs. For example, there can
be no guarantee that any mAb programs Arsanis is developing will
successfully commence or complete necessary preclinical and
clinical development phases, or that development of any of Arsanis'
product candidates will successfully continue. There can be no
guarantee that any positive developments in Arsanis' business will
result in stock price appreciation. Management's expectations and,
therefore, any forward-looking statements in this press release
could also be affected by risks and uncertainties relating to a
number of other important factors, including: Arsanis' results of
clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. FDA and other regulatory authorities, investigational review
boards at clinical trial sites and publication review bodies;
Arsanis' ability to obtain and maintain requisite regulatory
approvals and to enroll patients in its planned and ongoing
clinical trials; unplanned cash requirements and expenditures;
competitive factors; Arsanis' ability to obtain, maintain and
enforce patent and other intellectual property protection for any
product candidates it is developing; Arsanis' ability to maintain
key collaborations; and general economic and market conditions.
These and other risks are described in greater detail under the
caption "Risk Factors" included in Arsanis’ public filings with the
Securities and Exchange Commission. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Arsanis expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180417005151/en/
Media Contact:Ten Bridge CommunicationsKrystle Gibbs,
508-479-6358krystle@tenbridgecommunications.comorInvestor
Contact:Arsanis, Inc.Michael Gray, 781-819-5201Chief Operating
and Chief Financial Officermike.gray@arsanis.com
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jul 2023 bis Jul 2024